心臓マーカー検査のグローバル市場予測(~2028):トロポニン、CK-MB、BNP、hs-CRP、ミオグロビン

■ 英語タイトル:Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria - Global Forecast to 2028

調査会社MarketsandMarkets社が発行したリサーチレポート(データ管理コード:MD4673-23)■ 発行会社/調査会社:MarketsandMarkets
■ 商品コード:MD4673-23
■ 発行日:2023年10月25日
■ 調査対象地域:グローバル
■ 産業分野:医療
■ ページ数:216
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥752,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥1,010,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,238,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[心臓マーカー検査のグローバル市場予測(~2028):トロポニン、CK-MB、BNP、hs-CRP、ミオグロビン]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

“世界の心臓マーカー検査市場は、2022年の41億米ドルから2028年には69億米ドルに達し、予測期間中のCAGRは9.4%で成長すると予測” 予測される心臓マーカー検査の市場成長の急増は、魅力的な利点の合流によって支えられています。特に、心臓マーカー検査は、人口の高齢化、心血管疾患の症例の増加、新規の心臓バイオマーカーを発見するための公的/私的組織による研究と資金提供のイニシアティブの増加が原動力となっています。さらに、心臓病診断の有効性が向上し、心不全疾患の早期発見が増加していることから、心臓マーカー検査が最前線のソリューションとして位置づけられ、高度な治療手段に対する需要が高まっています。このような要因の収束により、市場は堅調な拡大局面を迎えることが予想され、その結果、今後予測される数年間における心臓マーカー検査の採用状況が形成されることになります。

“トロポニンIおよびTセグメントが2022-2028年に最大市場シェアを記録”
バイオマーカーの種類に基づいて、心臓マーカー検査市場は、トロポニンIおよびT、クレアチンキナーゼ-MB(CK-MB)、脳性ナトリウム利尿ペプチド(BNPおよびNT-PROBNP)、ミオグロビン、高感度C反応性タンパク質(hs-CRP)、およびその他の心臓バイオマーカーにセグメント化されます。2022-2028年の予測期間では、トロポニンIとTセグメントが最大の市場シェアを記録。このセグメントの成長を後押ししているのは、優れた感度と特異性、上昇時間の長さ(4~8時間で上昇し、10~24時間でピークに達し、10日間かけて低下する)、転帰の迅速な予測といった要因です。さらに、検査技師は他のバイオマーカーと比較して、これらのマーカーの活用に習熟しており、同分野の発展にさらに拍車をかけています。

“2022年、エンドユーザー別心臓マーカー検査市場で最大のシェアを占めた検査施設セグメント”
エンドユーザーに基づき、心臓マーカー検査市場はラボ検査施設、学術機関、ポイントオブケア検査施設に区分されます。2022年には、ラボ検査施設セグメントが世界の心臓マーカー検査市場で61.2%の最大シェアを占めました。このセグメントの成長は、検査効率の向上、ポイントオブケア検査と比較して優れた感度と診断精度、ポイントオブケア検査よりもラボ検査への強い嗜好などの要因によって推進されています。

“アジア太平洋は予測期間中に市場の著しい成長率を記録”
予測期間2023-2028年において、APAC地域は予測期間中に市場で著しい成長率を記録する見込みです。アジア太平洋は、インド、中国、日本、オーストラリア、韓国、RoAPACで構成されています。アジア太平洋(APAC)地域は、心臓マーカー検査の市場成長率が大幅に上昇しています。

この成長にはいくつかの要因があります:
アジア太平洋市場は、医療インフラの強化を目的とした新興国の政府機関による投資の増加により成長を遂げています。さらに、独立系臨床検査機関の増加、患者数の増加、アジア太平洋における心臓検査製品の提供を拡大するための業界各社の戦略的イニシアティブも、市場の追い風となっています。

本レポートで参照した主要参入企業の内訳は以下の通りです:
- 企業タイプ別:ティア1-43%、ティア2-30%、ティア3-27%
- 役職別:Cレベル-10%、ディレクターレベル-15%、その他-75%
- 地域別:北米-40%、ヨーロッパ-30%、アジア太平洋-23%、中南米-5%、中東・アフリカ-2%

この市場における主なプレーヤーには、F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), ), Thermo Fisher Scientific Inc. (US)などが含まれます。

調査範囲:
- 製品、バイオマーカータイプ、疾患、エンドユーザー、地域に基づいてマーカー検査市場を調査しています。
- 市場成長に影響を与える要因(促進要因、阻害要因、機会、課題など)を分析しています。
- 利害関係者向けに市場の機会と課題を評価し、市場リーダー向けに競争環境の詳細を提供します。
- 世界の心臓マーカー検査市場の成長動向、展望、貢献に関してミクロ市場を調査しています。
- 主要5地域に関して市場セグメントの収益を予測しています。

レポート購入の主な利点:
本レポートは、包括的なデータの徹底的な分析を通じて、新規参入企業/市場リーダー/小規模企業の心臓マーカー検査市場における投資評価の実行可能性を支援することにより、強固なリスク評価を促進し、十分な情報に基づいた投資決定を可能にします。用途、エンドユーザー、地域などの詳細な市場細分化により、的確なセグメントターゲティングのためのテーラーメイドの洞察が得られます。また、極めて重要なトレンド、課題、成長触媒、展望を網羅的に評価することで、鋭い洞察力による戦略的意思決定を支援します。

本レポートは、以下のポイントに関する洞察を提供します:
- 主な推進要因(心血管疾患の有病率の増加、世界的な高齢者人口の増加とそれに伴う心臓疾患の増加、新規心臓バイオマーカーの同定に向けた進行中の臨床試験)、阻害要因(サンプル収集・保管に関する技術的問題、不利な規制プロセス、限定的な償還構造)、 心臓マーカー検査市場の成長に影響を与える機会(心臓バイオマーカーを用いたPOCT(Point of Care Testing)、高成長の機会を提供する新興市場、心血管疾患の新規心臓バイオマーカーに関する進行中の研究)、課題(バイオマーカーアッセイのバリデーションに関連する課題)の分析しました。
- 製品開発/イノベーション:心臓マーカー検査市場における今後の技術、研究開発活動、新製品・サービスの発売に関する詳細な洞察を掲載しています。
- 市場開発:有利な市場に関する包括的な情報-当レポートでは、さまざまな地域の心臓マーカー検査市場を分析しています。
- 市場の多様化:心臓マーカー検査市場における新製品、未開拓の地域、最近の開発、投資に関する詳細な情報を掲載しています。
- 競合評価:F.Hoffmann-La Roche AG (スイス)、Abbott Laboratories (米国)、Danaher Corporation (米国)、Siemens Healthineers AG (ドイツ) などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価しています。

1 イントロダクション
2 調査方法
3 エグゼクティブサマリー
4 プレミアムインサイト
5 市場概要
6 世界の心臓マーカー検査市場分析:製品別
7 世界の心臓マーカー検査市場分析:疾患別
8 世界の心臓マーカー検査市場分析:バイオマーカー種類別
9 世界の心臓マーカー検査市場分析:エンドユーザー別
10 世界の心臓マーカー検査市場分析:地域別
11 競争状況
12 企業情報
13 付録

*** レポート目次(コンテンツ)***

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY 29
1.3 MARKET SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 REGIONS COVERED 30
1.4 YEARS CONSIDERED 30
1.5 CURRENCY 31
1.6 RESEARCH LIMITATIONS 31
1.7 MARKET STAKEHOLDERS 31
1.8 SUMMARY OF CHANGES 31
1.8.1 RECESSION IMPACT 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.2 RESEARCH DESIGN 34
2.2.1 SECONDARY RESEARCH 34
FIGURE 1 KEY DATA FROM SECONDARY SOURCES 36
2.2.2 PRIMARY RESEARCH 36
2.2.2.1 Primary sources 37
2.2.2.2 Key industry insights 38
2.2.2.3 Breakdown of primaries 38
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 38
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 39
2.3 MARKET SIZE ESTIMATION 39
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 40
2.3.1 BOTTOM-UP APPROACH 41
2.3.2 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH 41
FIGURE 5 CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION) 41
2.3.3 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION 42
FIGURE 6 CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 42
2.3.4 APPROACH 3: TOP-DOWN APPROACH 43
2.3.5 APPROACH 4: PRIMARY INTERVIEWS 43
FIGURE 7 CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 43
2.4 DATA TRIANGULATION AND MARKET BREAKDOWN 44
FIGURE 8 DATA TRIANGULATION METHODOLOGY 45
2.5 MARKET SHARE ASSESSMENT 46
2.6 STUDY ASSUMPTIONS 46
2.7 RISK ASSESSMENT 46
TABLE 1 LIMITATIONS AND ASSOCIATED RISKS 46
2.8 GROWTH RATE ASSUMPTIONS 47
2.9 RECESSION IMPACT 47
3 EXECUTIVE SUMMARY 48
FIGURE 9 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2023 VS. 2028 (USD MILLION) 48
FIGURE 10 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 49
FIGURE 11 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION) 49
FIGURE 12 CARDIAC MARKER TESTING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 50
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF CARDIAC MARKER TESTING MARKET 51
4 PREMIUM INSIGHTS 52
4.1 CARDIAC MARKER TESTING MARKET OVERVIEW 52
FIGURE 14 RISING PREVALENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 52
4.2 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY AND END USER, 2022 53
FIGURE 15 LABORATORY TESTING FACILITIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 53
4.3 CARDIAC MARKER TESTING MARKET: REGIONAL MIX 54
FIGURE 16 NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 54
4.4 CARDIAC MARKER TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
FIGURE 18 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
5.1.1 DRIVERS 57
5.1.1.1 Rising prevalence of cardiovascular diseases 57
5.1.1.2 Increasing geriatric population and subsequent rise in heart conditions worldwide 57
5.1.1.3 Growing research and funding initiatives from public and private organizations 58
5.1.1.4 Rising clinical studies for identification of novel cardiac biomarkers 58
5.1.2 RESTRAINTS 58
5.1.2.1 Technical issues related to sample collection and storage 58
5.1.2.2 Unfavorable regulatory processes and limited reimbursement structure 59
5.1.3 OPPORTUNITIES 60
5.1.3.1 Point-of-care testing with cardiac biomarkers 60
5.1.3.2 Ongoing research on novel cardiac biomarkers for cardiovascular diseases 60
5.1.3.3 Emerging markets 61
5.1.4 CHALLENGES 61
5.1.4.1 Challenges associated with biomarker assay validation 61
5.2 KEY STAKEHOLDERS AND BUYING CRITERIA 62
5.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 62
FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CARDIAC MARKER TESTING MARKET 62
TABLE 2 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY PRODUCT SEGMENTS (%) 62
5.3 PORTER’S FIVE FORCES ANALYSIS 62
TABLE 3 CARDIAC MARKER TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 63
5.3.1 THREAT OF NEW ENTRANTS 63
5.3.2 THREAT OF SUBSTITUTES 63
5.3.3 BARGAINING POWER OF SUPPLIERS 63
5.3.4 BARGAINING POWER OF BUYERS 63
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 64
5.4 REGULATORY ANALYSIS 64
5.4.1 US 64
TABLE 4 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 65
5.4.2 EUROPE 65
TABLE 5 EUROPE: CLASSIFICATION OF IVD DEVICES 65
5.4.3 JAPAN 66
TABLE 6 JAPAN: CLASSIFICATION OF IVD REAGENTS 66
TABLE 7 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 66
5.5 REIMBURSEMENT SCENARIO 66
TABLE 8 REIMBURSEMENT CODES FOR VARIOUS BIOMARKERS 67
5.6 ECOSYSTEM MAPPING 68
5.7 VALUE CHAIN ANALYSIS 68
5.7.1 RESEARCH & DEVELOPMENT 68
5.7.2 PROCUREMENT AND PRODUCT DEVELOPMENT 68
5.7.3 MARKETING, SALES AND DISTRIBUTION, AND POST-SALES SERVICES 68
FIGURE 20 VALUE CHAIN ANALYSIS OF CARDIAC MARKER TESTING MARKET 69
5.8 SUPPLY CHAIN ANALYSIS 69
5.8.1 PROMINENT COMPANIES 69
5.8.2 SMALL & MEDIUM-SIZED COMPANIES 69
5.8.3 END USERS 69
FIGURE 21 SUPPLY CHAIN ANALYSIS OF CARDIAC MARKER TESTING MARKET 70
5.9 PRICING ANALYSIS 70
TABLE 9 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER TROPONIN I AND T TEST KITS, 2021 70
TABLE 10 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER BPN AND NT-PROBNP TEST KITS, 2021 71
TABLE 11 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER MYOGLOBIN TEST KITS, 2021 71
TABLE 12 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER CK-MB TEST KITS, 2022 71
TABLE 13 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER C-REACTIVE PROTEIN (HS-CRP) TEST KITS, 2022 71
TABLE 14 AVERAGE SELLING PRICE TREND OF CARDIAC MARKER TEST KITS, BY COUNTRY, 2021–2023 (USD) 72
5.10 PATENT ANALYSIS 72
FIGURE 22 TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING, JANUARY 2012–SEPTEMBER 2022 73
FIGURE 23 TOP 10 PATENT OWNERS FOR CARDIAC MARKER TESTING, JANUARY 2012–SEPTEMBER 2022 73
5.11 TRADE ANALYSIS 73
TABLE 15 IMPORT DATA FOR CARDIAC MARKER TESTING (HS CODE 3822), BY COUNTRY, 2018–2022 (USD THOUSAND) 74
TABLE 16 EXPORT DATA FOR CARDIAC MARKER TESTING (HS CODE 3822), BY COUNTRY, 2018–2022 (USD THOUSAND) 74
5.12 CASE STUDIES 75
TABLE 17 CASE STUDY: BREAKTHROUGH IN ACUTE MYOCARDIAL INFARCTION DIAGNOSIS WITH HIGH-SENSITIVITY TROPONIN I ASSAYS 75
5.13 KEY CONFERENCES AND EVENTS, 2023–2024 75
TABLE 18 CARDIAC MARKER TESTING MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS IN 2023–2024 75
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 76
FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 76
5.15 IMPACT OF RECESSION ON CARDIAC MARKER TESTING MARKET 76
6 CARDIAC MARKER TESTING MARKET, BY PRODUCT 78
6.1 INTRODUCTION 79
TABLE 19 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 79
6.2 REAGENTS & KITS 79
6.2.1 RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND 79
TABLE 20 CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 80
TABLE 21 CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 80
6.3 INSTRUMENTS 81
TABLE 22 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 81
TABLE 23 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 81
TABLE 24 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 82
6.3.1 CHEMILUMINESCENCE 82
6.3.1.1 Most preferred method for quantifying cardiac biomarkers 82
TABLE 25 CHEMILUMINESCENCE INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 83
TABLE 26 CHEMILUMINESCENCE INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 83
6.3.2 IMMUNOFLUORESCENCE 84
6.3.2.1 Demand for stable and safer reagents to support market growth 84
TABLE 27 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 84
TABLE 28 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 85
6.3.3 ELISA 85
6.3.3.1 Long shelf life and ease of use to propel growth 85
TABLE 29 ELISA INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 85
TABLE 30 ELISA INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 86
6.3.4 IMMUNOCHROMATOGRAPHY 86
6.3.4.1 Increasing use in point-of-care settings to propel adoption 86
TABLE 31 IMMUNOCHROMATOGRAPHY INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 87
TABLE 32 IMMUNOCHROMATOGRAPHY INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 87
7 CARDIAC MARKER TESTING MARKET, BY INDICATION 88
7.1 INTRODUCTION 89
TABLE 33 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2021–2028 (USD MILLION) 89
7.2 MYOCARDIAL INFARCTION 89
7.2.1 AVAILABILITY OF HIGH-SENSITIVITY BIOMARKERS FOR DETECTION TO DRIVE MARKET 89
TABLE 34 CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2021–2028 (USD MILLION) 90
7.3 CONGESTIVE HEART FAILURE 90
7.3.1 INCREASING USE OF MULTIMARKER TESTING TO SUPPORT MARKET GROWTH 90
TABLE 35 CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2021–2028 (USD MILLION) 91
7.4 ACUTE CORONARY SYNDROME 91
7.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS 91
TABLE 36 CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2021–2028 (USD MILLION) 92
7.5 ATHEROSCLEROSIS 92
7.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE MARKET 92
TABLE 37 CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2021–2028 (USD MILLION) 93
7.6 ISCHEMIA 93
7.6.1 INCREASE IN CARDIAC ISCHEMIA TO BOOST DEMAND FOR CARDIAC MARKER TESTS 93
TABLE 38 CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION, 2021–2028 (USD MILLION) 94
8 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE 95
8.1 INTRODUCTION 96
TABLE 39 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 96
8.2 TROPONIN I AND T 96
8.2.1 HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET 96
TABLE 40 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY INDICATION, 2021–2028 (USD MILLION) 97
TABLE 41 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 97
TABLE 42 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 98
8.3 CREATINE KINASE-MB 98
8.3.1 POOR SPECIFICITY AND BRIEF ELEVATION DURATION TO HAMPER MARKET GROWTH 98
TABLE 43 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY INDICATION, 2021–2028 (USD MILLION) 99
TABLE 44 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 99
TABLE 45 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 100
8.4 BRAIN NATRIURETIC PEPTIDE 100
8.4.1 USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION 100
TABLE 46 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY INDICATION, 2021–2028 (USD MILLION) 101
TABLE 47 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY END USER, 2021–2028 (USD MILLION) 101
TABLE 48 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY REGION, 2021–2028 (USD MILLION) 102
8.5 MYOGLOBIN 102
8.5.1 USED TO ASSESS PATIENTS WITH CHEST PAIN IN EMERGENCY DEPARTMENT SETTINGS 102
TABLE 49 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY INDICATION, 2021–2028 (USD MILLION) 102
TABLE 50 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY END USER, 2021–2028 (USD MILLION) 103
TABLE 51 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2021–2028 (USD MILLION) 103
8.6 HIGH-SENSITIVITY C-REACTIVE PROTEIN 103
8.6.1 INCREASING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL ADOPTION 103
TABLE 52 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY INDICATION, 2021–2028 (USD MILLION) 104
TABLE 53 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY END USER, 2021–2028 (USD MILLION) 104
TABLE 54 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY REGION, 2021–2028 (USD MILLION) 105
8.7 OTHER CARDIAC BIOMARKERS 105
TABLE 55 OTHER CARDIAC BIOMARKERS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 106
TABLE 56 OTHER CARDIAC BIOMARKERS MARKET, BY END USER, 2021–2028 (USD MILLION) 106
TABLE 57 OTHER CARDIAC BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 107
9 CARDIAC MARKER TESTING MARKET, BY END USER 108
9.1 INTRODUCTION 109
TABLE 58 CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 109
9.2 LABORATORY TESTING FACILITIES 109
TABLE 59 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 60 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2021–2028 (USD MILLION) 110
9.2.1 HOSPITAL LABORATORIES 110
9.2.1.1 Early diagnosis associated with in-house labs to support market growth 110
TABLE 61 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 111
9.2.2 REFERENCE LABORATORIES 111
9.2.2.1 Affordable and time-efficient services associated with reference laboratories to drive market 111
TABLE 62 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 112
9.2.3 CONTRACT TESTING LABORATORIES 112
9.2.3.1 Ability to perform multiple tests to propel market 112
TABLE 63 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 112
9.3 ACADEMIC INSTITUTES 113
9.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET 113
TABLE 64 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 113
9.4 POINT-OF-CARE TESTING FACILITIES 113
9.4.1 EARLY DETECTION AND LOWER TURNAROUND TIME TO PROPEL MARKET 113
TABLE 65 CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING FACILITIES, BY REGION, 2021–2028 (USD MILLION) 114
10 CARDIAC MARKER TESTING MARKET, BY REGION 115
10.1 INTRODUCTION 116
TABLE 66 CARDIAC MARKER TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 116
10.2 NORTH AMERICA 117
10.2.1 NORTH AMERICA: RECESSION IMPACT 117
FIGURE 25 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT 117
TABLE 67 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 68 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 118
TABLE 69 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 118
TABLE 70 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 119
TABLE 71 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 119
10.2.2 US 120
10.2.2.1 Growing support from NIH for development of novel cardiac biomarkers to drive market 120
TABLE 72 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 120
10.2.3 CANADA 120
10.2.3.1 Government initiatives to support market growth 120
TABLE 73 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 121
10.3 EUROPE 121
10.3.1 EUROPE: RECESSION IMPACT 121
TABLE 74 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 75 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 122
TABLE 76 EUROPE: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 122
TABLE 77 EUROPE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 123
TABLE 78 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 123
10.3.2 GERMANY 123
10.3.2.1 Favorable government policies to support market growth 123
TABLE 79 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 124
10.3.3 FRANCE 124
10.3.3.1 Rising geriatric population to drive market 124
TABLE 80 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 124
10.3.4 UK 125
10.3.4.1 Government initiatives to boost adoption of cardiac biomarkers 125
TABLE 81 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125
10.3.5 ITALY 125
10.3.5.1 Adoption of advanced diagnostic technologies to drive market 125
TABLE 82 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 126
10.3.6 SPAIN 126
10.3.6.1 Establishment of large and advanced laboratories to drive uptake of cardiac marker testing 126
TABLE 83 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 126
10.3.7 REST OF EUROPE 126
TABLE 84 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 127
10.4 ASIA PACIFIC 127
10.4.1 ASIA PACIFIC: RECESSION IMPACT 127
FIGURE 26 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT 128
TABLE 85 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 86 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 129
TABLE 87 ASIA PACIFIC: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 130
TABLE 88 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 130
TABLE 89 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 131
10.4.2 JAPAN 131
10.4.2.1 Presence of advanced laboratory facilities to drive market 131
TABLE 90 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 131
10.4.3 CHINA 132
10.4.3.1 Growing number of independent clinical laboratories to drive demand for cardiac markers 132
TABLE 91 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 132
10.4.4 INDIA 132
10.4.4.1 Presence of large patient population to drive demand 132
TABLE 92 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 133
10.4.5 AUSTRALIA 133
10.4.5.1 Increasing healthcare expenditure to support market growth 133
TABLE 93 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 133
10.4.6 SOUTH KOREA 134
10.4.6.1 Growing number of private hospitals to drive adoption of advanced testing services 134
TABLE 94 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 134
10.4.7 REST OF ASIA PACIFIC 134
TABLE 95 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 134
10.5 LATIN AMERICA 135
10.5.1 LATIN AMERICA: RECESSION IMPACT 135
TABLE 96 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 97 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 136
TABLE 98 LATIN AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 136
TABLE 99 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 137
TABLE 100 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 137
10.5.2 BRAZIL 137
10.5.2.1 Increasing government support for advancements in healthcare to support market growth 137
TABLE 101 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 138
10.5.3 MEXICO 138
10.5.3.1 Rising demand for technologically advanced products to drive uptake of cardiac markers 138
TABLE 102 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 138
10.5.4 REST OF LATIN AMERICA 139
TABLE 103 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 139
10.6 MIDDLE EAST & AFRICA 139
10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE DEMAND FOR ADVANCED MARKERS 139
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 139
TABLE 104 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 140
TABLE 105 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 140
TABLE 106 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 141
TABLE 107 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 141
10.6.3 GCC COUNTRIES 141
11 COMPETITIVE LANDSCAPE 142
11.1 OVERVIEW 142
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 142
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CARDIAC MARKER TESTING MARKET 143
11.3 REVENUE SHARE ANALYSIS 144
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET, 2018–2022 (USD MILLION) 144
11.4 MARKET RANKING ANALYSIS 145
11.5 COMPANY EVALUATION MATRIX 147
11.5.1 STARS 147
11.5.2 EMERGING LEADERS 147
11.5.3 PERVASIVE PLAYERS 147
11.5.4 PARTICIPANTS 147
FIGURE 29 CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION MATRIX, 2022 148
11.6 STARTUP/SME EVALUATION MATRIX 149
11.6.1 PROGRESSIVE COMPANIES 149
11.6.2 STARTING BLOCKS 149
11.6.3 RESPONSIVE COMPANIES 149
11.6.4 DYNAMIC COMPANIES 149
FIGURE 30 CARDIAC MARKER TESTING MARKET: STARTUP/SME EVALUATION MATRIX, 2022 150
11.7 COMPANY FOOTPRINT 151
TABLE 108 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET 151
TABLE 109 PRODUCT FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET 152
TABLE 110 REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET 153
11.8 COMPETITIVE SCENARIOS AND TRENDS 154
TABLE 111 KEY PRODUCT LAUNCHES 154
TABLE 112 KEY DEALS 155
TABLE 113 OTHER KEY DEVELOPMENTS 156
12 COMPANY PROFILES 157
12.1 KEY PLAYERS 157
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 F. HOFFMANN-LA ROCHE AG 157
TABLE 114 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW 157
FIGURE 31 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2022) 158
12.1.2 ABBOTT LABORATORIES 162
TABLE 115 ABBOTT LABORATORIES: COMPANY OVERVIEW 162
FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 163
12.1.3 SIEMENS HEALTHINEERS AG 166
TABLE 116 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 166
FIGURE 33 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 167
12.1.4 DANAHER CORPORATION 170
TABLE 117 DANAHER CORPORATION: COMPANY OVERVIEW 170
FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 171
12.1.5 BIO-RAD LABORATORIES, INC. 173
TABLE 118 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 173
FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 174
12.1.6 BIOMÉRIEUX SA 176
TABLE 119 BIOMÉRIEUX SA: COMPANY OVERVIEW 176
FIGURE 36 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2022) 177
12.1.7 BECTON, DICKINSON AND COMPANY 178
TABLE 120 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 178
FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 179
12.1.8 THERMO FISHER SCIENTIFIC INC. 181
TABLE 121 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 181
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 182
12.1.9 DIASORIN S.P.A. 184
TABLE 122 DIASORIN S.P.A.: COMPANY OVERVIEW 184
FIGURE 39 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022) 185
12.1.10 PERKINELMER INC. 187
TABLE 123 PERKINELMER INC.: COMPANY OVERVIEW 187
FIGURE 40 PERKINELMER INC.: COMPANY SNAPSHOT (2022) 188
12.1.11 TOSOH CORPORATION 190
TABLE 124 TOSOH CORPORATION: COMPANY OVERVIEW 190
FIGURE 41 TOSOH CORPORATION: COMPANY SNAPSHOT (2023) 191
12.1.12 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION) 193
TABLE 125 LSI MEDIENCE CORPORATION: COMPANY OVERVIEW 193
FIGURE 42 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022) 194
12.1.13 QUIDEL CORPORATION 195
TABLE 126 QUIDEL CORPORATION: COMPANY OVERVIEW 195
FIGURE 43 QUIDEL CORPORATION: COMPANY SNAPSHOT (2022) 196
12.1.14 RANDOX LABORATORIES 198
TABLE 127 RANDOX LABORATORIES: COMPANY OVERVIEW 198
12.1.15 GUANGZHOU WONDFO BIOTECH CO., LTD. 200
TABLE 128 GUANGZHOU WONDFO BIOTECH CO., LTD.: BUSINESS OVERVIEW 200
12.1.16 BODITECH MED INC. 202
TABLE 129 BODITECH MED INC.: BUSINESS OVERVIEW 202
12.1.17 TULIP DIAGNOSTICS (P) LTD. 204
TABLE 130 TULIP DIAGNOSTICS (P) LTD.: BUSINESS OVERVIEW 204
12.1.18 BTNX INC. 205
TABLE 131 BTNX INC.: BUSINESS OVERVIEW 205
12.1.19 RESPONSE BIOMEDICAL 207
TABLE 132 RESPONSE BIOMEDICAL: BUSINESS OVERVIEW 207
12.1.20 ALFA SCIENTIFIC DESIGNS, INC. 209
TABLE 133 ALFA SCIENTIFIC DESIGNS, INC.: BUSINESS OVERVIEW 209
12.2 OTHER PLAYERS 210
12.2.1 CTK BIOTECH, INC. 210
12.2.2 CREATIVE DIAGNOSTICS 211
12.2.3 LIFESIGN LLC 211
12.2.4 CARDIOGENICS HOLDINGS INC. 212
12.2.5 ATLAS MEDICAL GMBH 212
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 213
13.1 DISCUSSION GUIDE 213
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 218
13.3 CUSTOMIZATION OPTIONS 220
13.4 RELATED REPORTS 220
13.5 AUTHOR DETAILS 221



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(MD4673-23 )"心臓マーカー検査のグローバル市場予測(~2028):トロポニン、CK-MB、BNP、hs-CRP、ミオグロビン" (英文:Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria - Global Forecast to 2028)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。